BELVIN MARCIA 4
4 · CytomX Therapeutics, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) SVP Marcia Belvin Sells 31,492 Shares
What Happened
- Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics (CTMX), sold 31,492 shares on 2026-03-17 at $6.42 per share, generating proceeds of $202,273. This was a sale (not a purchase) and was reported on a Form 4 filed 2026-03-19.
Key Details
- Transaction date and price: 2026-03-17 at $6.42 per share.
- Total proceeds: $202,273 for 31,492 shares.
- Purpose/footnote: The filing states the shares were sold solely to satisfy tax or other government withholding obligations in connection with RSU vesting (Footnote F1).
- Holdings noted: Filing indicates holdings include 135,833 RSUs (Footnote F2).
- Timeliness: Form 4 was filed on 2026-03-19 (covers the 3/17 transaction) and appears to be filed within the required reporting window.
Context
- This was a withholding-related sale tied to RSU vesting (a routine, administrative transaction) rather than a discretionary sell for investment reasons. Such tax-withholding sales are common and do not necessarily indicate management sentiment about the company’s stock.
Insider Transaction Report
Form 4
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-17$6.42/sh−31,492$202,273→ 300,760 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 135,833 RSUs.
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin|2026-03-19